These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21311411)

  • 1. The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease.
    Haglund S; Vikingsson S; Söderman J; Hindorf U; Grännö C; Danelius M; Coulthard S; Peterson C; Almer S
    Ther Drug Monit; 2011 Apr; 33(2):200-8. PubMed ID: 21311411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
    Haglund S; Taipalensuu J; Peterson C; Almer S
    Br J Clin Pharmacol; 2008 Jan; 65(1):69-77. PubMed ID: 17662091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis.
    Hindorf U; Jahed K; Bergquist A; Verbaan H; Prytz H; Wallerstedt S; Werner M; Olsson R; Björnsson E; Peterson C; Almer SH
    J Hepatol; 2010 Jan; 52(1):106-11. PubMed ID: 19906459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.
    Chouchana L; Narjoz C; Roche D; Golmard JL; Pineau B; Chatellier G; Beaune P; Loriot MA
    Pharmacogenomics; 2014 Apr; 15(6):745-57. PubMed ID: 24897283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
    Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
    Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
    Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
    Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
    Schedel J; Gödde A; Schütz E; Bongartz TA; Lang B; Schölmerich J; Müller-Ladner U
    Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITPA Activity in Adults and Children Treated With or Without Azathioprine: Relationship Between TPMT Activity, Thiopurine Metabolites, and Co-medications.
    Citterio-Quentin A; Moulsma M; Gustin MP; Boulieu R
    Ther Drug Monit; 2017 Oct; 39(5):483-491. PubMed ID: 28650902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of inosine 5'-monophosphate dehydrogenase activity in red blood cells of thiopurine-treated patients using HPLC.
    Beringer A; Citterio-Quentin A; Otero RO; Gustin C; Clarke R; Salvi JP; Boulieu R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Feb; 1044-1045():194-199. PubMed ID: 28110955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
    Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
    Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.